ADP/P2Y1 aggravates inflammatory bowel disease through ERK5-mediated NLRP3 inflammasome activation

  • Chengfei Zhang
  • , Juliang Qin
  • , Su Zhang
  • , Na Zhang
  • , Binhe Tan
  • , Stefan Siwko
  • , Ying Zhang
  • , Qin Wang
  • , Jinlian Chen
  • , Min Qian
  • , Mingyao Liu*
  • , Bing Du*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Inflammasomes are essential for inflammation and pathogen elimination in response to microbial infection and endogenous danger signals. However, the mechanism of inflammasome activation by endogenous danger signals mediated posttranslational modification and the connection between inflammasomes and inflammatory diseases remains elusive. In this study, we found that ADP was highly released from injured colonic tissue as a danger signal during inflammatory bowel disease. Consequently, extracellular ADP activated the NLRP3 inflammasome through P2Y1 receptor-mediated calcium signaling, which led to the maturation and secretion of IL-1β and further aggravation of experimental colitis. Genetic ablation or pharmacological blockade of the P2Y1 receptor significantly ameliorated DSS-induced colitis and endotoxic shock through reducing NLRP3 inflammasome activation. Moreover, ERK5-mediated tyrosine phosphorylation of ASC was essential for activation of the NLRP3 inflammasome. Thus, our study provides a novel theoretical basis for posttranslational modification of ASC in NLRP3 inflammasome activation and revealed that ADP/P2Y1 is a potential drug target for inflammatory bowel disease.

Original languageEnglish
Pages (from-to)931-945
Number of pages15
JournalMucosal Immunology
Volume13
Issue number6
DOIs
StatePublished - 1 Nov 2020

Fingerprint

Dive into the research topics of 'ADP/P2Y1 aggravates inflammatory bowel disease through ERK5-mediated NLRP3 inflammasome activation'. Together they form a unique fingerprint.

Cite this